What is the 13F Pro Quality Score for INGN?

13F Pro ranks Inogen Inc (INGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INGN's current score at https://13fpro.ai/research/INGN (free sign-up required for the full ranking).

Which hedge funds own the most INGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INGN include BlackRock,, ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/INGN as soon as new 13F filings post.

Where does 13F Pro source INGN data?

All Inogen Inc fundamentals and ownership data come directly from SEC EDGAR. Inogen Inc files with the SEC under CIK 1294133. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INGN in?

Inogen Inc (INGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INGN research updated on 13F Pro?

INGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inogen Inc(INGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1294133 INGN stock profile & AI dashboard →

13F Pro Quality Score

35.5/100

Rank #2,144 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

60.8/100

Profitability

31.3/100

Balance Sheet

19.7/100

Earnings Quality

30.0/100

Free Cash Flow

22.3/100

Institutional Flow

58.3/100

Revenue Scale

29.6/100

Dilution Risk

38.9/100

INGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Inogen Inc (INGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INGN at 35.5/100 on a 32-signal composite quality model, placing it at rank #2,144 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (19.7) and free cash flow (22.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Inogen Inc reports quarterly revenue of $85.1M, net income of $-8.3M, an operating margin of -11.0%. Top institutional holders of INGN by reported 13-F value include BlackRock,, ARMISTICE CAPITAL,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INGN trades on the Nasdaq exchange and files with the SEC under CIK 1294133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inogen Inc directly from SEC EDGAR. Inogen Inc's 13F Pro composite quality score has ranged between 8 and 55 since 2021, currently 35.5 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Inogen Inc

Quirks, history, and lore behind INGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of $300–400 million — modest by pharma standards, but it dominates a niche where patients literally can't breathe without it.
3
The History
Founded in the early 2000s, it set out to solve a very specific frustration: why should patients needing supplemental oxygen be chained to a wall-mounted tank?
4
The Secret
Its core innovation is a portable oxygen concentrator — a device that pulls oxygen straight from ambient air, eliminating the need for heavy compressed-gas cylinders entirely.
5
The Lore
It sells directly to COPD and respiratory patients and also rents units through Medicare reimbursement — meaning grandma can take a stroll in the park without a cart of tanks in tow.
6
The Giveaway
Its name is a portmanteau of "innovative" and "oxygen," and its flagship devices let chronic lung patients travel by plane, hike, and live untethered for the first time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$85.1M

Net Income

Q1 2026

$-8.3M

Free Cash Flow

Q1 2026

$-6.9M

Operating Margin

Q1 2026

-11.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+3.9% YoY

$348.7MFY 2025

FY20 $308.5MFY21 $358.0MFY24 $335.7MFY25 $348.7M

Net Income

-36.6% YoY

$22.7MFY 2025

FY20 $-5.8MFY21 $6.3MFY24 $35.9MFY25 $22.7M

Operating Income

+29.0% YoY

$-30.2MFY 2025

FY20 $-12.0MFY21 $9.2MFY24 $-42.5MFY25 $-30.2M

EPS (Diluted)

+43.4% YoY

$-0.86FY 2025

FY20 $-0.27FY21 $-0.28FY24 $-1.52FY25 $-0.86

Total Assets

+0.8% YoY

$298.6MFY 2025

FY20 $461.9MFY21 $489.5MFY24 $296.2MFY25 $298.6M

Op. Cash Flow

-289.7% YoY

$-11.2MFY 2025

FY20 $37.0MFY21 $23.6MFY24 $5.9MFY25 $-11.2M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$348.7M +3.9%	$335.7M -6.2%	$358.0M +16.1%	$308.5M -14.8%	$361.9M +1.1%	$358.1M
Net Income	$22.7M -36.6%	$35.9M +466.7%	$6.3M +208.6%	$-5.8M -127.8%	$20.9M -59.6%	$51.8M
Operating Income	$-30.2M +29.0%	$-42.5M -560.1%	$9.2M +176.8%	$-12.0M -160.8%	$19.8M -47.8%	$37.9M
EPS (Diluted)	$-0.86 +43.4%	$-1.52 -442.9%	$-0.28 -3.7%	$-0.27 -128.7%	$0.94 -59.1%	$2.30
Total Assets	$298.6M +0.8%	$296.2M -39.5%	$489.5M +6.0%	$461.9M +3.2%	$447.3M +19.0%	$375.9M
Operating Cash Flow	$-11.2M -289.7%	$5.9M -75.0%	$23.6M -36.1%	$37.0M -8.8%	$40.6M -32.3%	$60.0M

AI Insight: INGN Financial Trends

Inogen remains persistently unprofitable across eight consecutive quarters with no clear path to operating breakeven.

• Revenue has been range-bound between $80M and $92M since Q2 2024, showing no meaningful growth trajectory.

• Operating losses have persisted every quarter, ranging from -$6M to -$11M, with Q1 2026 at -$9M.

• Equity has declined from $199M in Q2 2025 to $183M in Q1 2026, eroded by ongoing net losses.

⚠ Operating cash flow turned negative in Q4 2024 (-$3M), Q1 2025 (-$17M), Q4 2025 (-$1M), and Q1 2026 (-$7M) — a recurring cash burn pattern.

⚠ Equity has dropped $16M in two quarters from its $199M peak; continued losses could pressure the balance sheet further.

AI Insight: INGN Ratio Trends

Inogen remains deeply unprofitable across all metrics, with Q1 2026 ROE deteriorating to -18.2% — the worst since Q4 2024's seasonal trough.

• Operating margin worsened to -11.0% in Q1 2026 from -6.6% in Q2 2025, reversing the mid-year improvement.

• ROIC deteriorated to -20.4% in Q1 2026, the weakest reading outside Q4 2024's -26.2% seasonal low.

• Q2 2025 offered a brief bright spot — operating margin narrowed to -6.6% and ROIC improved to -12.3% — but gains faded immediately.

⚠ Q4 seasonality has now twice driven severe margin deterioration (-14.2% in Q4 2024, -11.4% in Q4 2025); monitor Q4 2026 closely.

⚠ NPM deepened to -9.8% in Q1 2026 vs. -7.5% in Q1 2025 — year-over-year deterioration signals no structural improvement yet.

⚠ D/E data is entirely absent; debt structure and liquidity runway cannot be assessed from available data.

Get alerted when INGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inogen Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INGN

BlackRock, Inc.
$10.2M1,647,084 sh
ARMISTICE CAPITAL, LLC
$7.4M1,200,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.4M1,036,705 sh
EverSource Wealth Advisors, LLC
$5.8M46,742 sh
AMERIPRISE FINANCIAL INC
$5.3M859,543 sh
DAFNA Capital Management LLC
$5.2M845,179 sh
Point72 Asset Management, L.P.
$4.0M642,366 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.8M613,529 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$3.6M586,159 sh
GOLDMAN SACHS GROUP INC
$3.6M580,100 sh

Fund	Value	Shares
BlackRock, Inc.	$10.2M	1,647,084
ARMISTICE CAPITAL, LLC	$7.4M	1,200,000
VANGUARD CAPITAL MANAGEMENT LLC	$6.4M	1,036,705
EverSource Wealth Advisors, LLC	$5.8M	46,742
AMERIPRISE FINANCIAL INC	$5.3M	859,543
DAFNA Capital Management LLC	$5.2M	845,179
Point72 Asset Management, L.P.	$4.0M	642,366
GEODE CAPITAL MANAGEMENT, LLC	$3.8M	613,529
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$3.6M	586,159
GOLDMAN SACHS GROUP INC	$3.6M	580,100

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INGN on your watchlist

Track score changes the day Inogen Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INGN a good stock to buy?

13F Pro's AI-powered analysis of Inogen Inc (INGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INGN are available on the INGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inogen Inc's investment landscape.